NCT03542175 2025-12-08
A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
Clinical Trials
9 trialsNCT03552471 2025-02-13
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT03840200 2023-10-30
A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
Hoffmann-La Roche
Phase 1 Completed
NCT04179396 2023-06-29
RAMP
pharmaand GmbH
Phase 1 Completed
NCT03499444 2023-06-09
A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor
pharmaand GmbH
Phase 1 Completed
NCT03521037 2023-06-09
Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor
pharmaand GmbH
Phase 1 Completed
NCT01009190 2023-06-08
A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens
pharmaand GmbH
Phase 1 Completed
NCT03954366 2023-06-08
Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives
pharmaand GmbH
Phase 1 Completed
NCT03101280 2020-10-22
A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer
Hoffmann-La Roche
Phase 1 Completed